Boston Scientific Corporation  

(Public, NYSE:BSX)   Watch this stock  
Find more results for bsx
-0.35 (-1.56%)
After Hours: 22.17 +0.08 (0.36%)
Oct 26, 7:56PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 21.82 - 22.54
52 week 15.67 - 24.79
Open 22.45
Vol / Avg. 18.70M/8.41M
Mkt cap 29.37B
P/E     -
Div/yield     -
EPS -0.26
Shares 1.36B
Beta 0.89
Inst. own 94%
Oct 31, 2016
Boston Scientific Corp Investor update at TCT16 (Transcatheter Cardiovascular Therapeutics) - 9:00AM EDT - Add to calendar
Oct 26, 2016
Q3 2016 Boston Scientific Corp Earnings Release
Oct 26, 2016
Q3 2016 Boston Scientific Corp Earnings Call - Webcast
Sep 21, 2016
Boston Scientific Corp VIVA Investor Update - Webcast
Sep 13, 2016
Boston Scientific Corp at Morgan Stanley Global Healthcare Conference - Webcast
Sep 7, 2016
Boston Scientific Corp at Wells Fargo Securities Healthcare Conference
Aug 16, 2016
Boston Scientific Corp at Wedbush PacGrow Healthcare Conference - Webcast
Aug 11, 2016
Boston Scientific Corp at Canaccord Genuity Growth Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -9.74% -3.20%
Operating margin -15.71% -4.37%
EBITD margin - 24.29%
Return on average assets -4.67% -1.36%
Return on average equity -13.10% -3.74%
Employees 25,000 -
CDP Score - 58 E


MARLBOROUGH, MA 01752-1234
United States - Map
+1-508-6834000 (Phone)
+1-508-6508923 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters.

Officers and directors

Michael F. Mahoney Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Joseph M. Fitzgerald Executive Vice President and President - Rhythm Management
Age: 52
Bio & Compensation  - Reuters
Daniel J. Brennan Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Timothy A. Pratt Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
Age: 66
Bio & Compensation  - Reuters
Supratim Bose Executive Vice President and President - Asia-Pacific, Middle East and Africa
Age: 63
Bio & Compensation  - Reuters
Keith D. Dawkins M.D. Global Chief Medical Officer, Executive Vice President
Age: 65
Bio & Compensation  - Reuters
Edward F. Mackey Executive Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Michael P. Phalen Executive Vice President and President - MedSurg
Age: 56
Bio & Compensation  - Reuters
Wendy Carruthers Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Kevin J. Ballinger Senior Vice President and President - Interventional Cardiology
Age: 43
Bio & Compensation  - Reuters